Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Scroll Up
Scroll Down

Unified Laboratory Intelligence for Impurity Resolution Management
Bookmark and Share

ACD Labs

Maximizing the effective patent life of a marketed drug is one of the main priorities for researchers. According to a March 2010 article in Nature, the estimated average cost for pharmaceutical companies to bring a new chemical entity (NCE) to market is approximately 1.8 billion and requires 13.5 years on average. Identifying and characterizing an impurity in a couple of days less time can literally equate to a gain of a million dollars in net present value. Being able to do this repeatedly as impurities are encountered through the drug development and acceptance of a drug substance can shave weeks, or even months, off the time to market, increasing returns by millions of dollars.

Unified Laboratory Intelligence (ULI) is a category of R&D informatics that combines software, algorithmic tools, and databases to form a scalable platform for the collection and unification of chemical, structural, and analytical data. ULI accumulates information and knowledge from successive projects across different chemistry disciplines to create a one-to-many chemical intelligence-from-information ‘live’ cycle. With ULI, scientists can easily search and quickly retrieve ‘live’ data to gain and apply intelligence and insight that improves decision-making. 

Further Information


SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!